Viona Pharmaceuticals Inc. has recalled 21,240 bottles of Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, which is a prescription medication used to control blood sugar in patients with type 2 diabetes. The recall was initiated because testing detected levels of N-Nitrosodimethylamine (NDMA) that exceed the acceptable daily intake limit. While NDMA is a common environmental contaminant, long-term exposure to levels above the safety limit may increase the risk of cancer. This recall affects specific 100-count bottles manufactured by Cadila Healthcare Ltd. and distributed nationwide.
The tablets contain N-Nitrosodimethylamine (NDMA) at levels higher than the FDA's Acceptable Daily Intake Limit. NDMA is classified as a probable human carcinogen, meaning long-term exposure above safety thresholds could potentially increase the risk of developing cancer.
Refund and medical guidance
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.